title: Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein.
abstract: Natural killer (NK) cells are at the crossroad between innate and adaptive immunity and play a major role in cancer immunosurveillance. NK cell stimulation depends on a balance between inhibitory and activating receptors, such as the stimulatory lectin-like receptor NKG2D. To redirect NK cells against tumor cells, we designed bifunctional proteins able to specifically bind tumor cells and to induce their lysis by NK cells, after NKG2D engagement. To this aim, we used the 'knob into hole' heterodimerization strategy, in which 'knob' and 'hole' variants were generated by directed mutagenesis within the CH3 domain of human IgG1 Fc fragments fused to an anti-CEA or anti-HER2 scFv or to the H60 murine ligand of NKG2D, respectively. We demonstrated the capacity of the bifunctional proteins produced to specifically coat tumor cells surface with H60 ligand. Most importantly, we demonstrated that these bifunctional proteins were able to induce an NKG2D-dependent and antibody-specific tumor cell lysis by murine NK cells. Overall, the results show the possibility to redirect NK cytotoxicity to tumor cells by a new format of recombinant bispecific antibody, opening the way of potential NK cell-based cancer immunotherapies by specific activation of the NKG2D receptor at the tumor site.
authors.affiliation: IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U896, Université Montpellier1, Montpellier F-34298, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Germain
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Campigna
authors.forename: Imed
authors.initials: I
authors.lastname: Salhi
authors.forename: Sébastien
authors.initials: S
authors.lastname: Morisseau
authors.forename: Isabelle
authors.initials: I
authors.lastname: Navarro-Teulon
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Mach
authors.forename: André
authors.initials: A
authors.lastname: Pèlegrin
authors.forename: Bruno
authors.initials: B
authors.lastname: Robert
mesh_terms: D000818:Animals; D015153:Blotting, Western; D016923:Cell Death / Q000276:immunology; D045744:Cell Line, Tumor; D003602:Cytotoxicity, Immunologic; D015180:Electrophoresis, Gel, Two-Dimensional; D058851:GPI-Linked Proteins; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000276:immunology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D015778:Minor Histocompatibility Antigens / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000378:metabolism
chemical_list: D058851:GPI-Linked Proteins; D036341:Intercellular Signaling Peptides and Proteins; D015778:Minor Histocompatibility Antigens; D011994:Recombinant Proteins; C423230:ULBP2 protein, human; C114735:minor H antigen H60
references.citation: Int J Cancer. 1989 Oct 15;44(4):738-43
references.pmid: 2793246
references.citation: Blood. 2005 Sep 1;106(5):1711-7
references.pmid: 15886320
references.citation: Cancer Res. 2003 Dec 15;63(24):8996-9006
references.pmid: 14695218
references.citation: Immunity. 2002 Jul;17(1):19-29
references.pmid: 12150888
references.citation: Nat Rev Microbiol. 2005 Jan;3(1):59-69
references.pmid: 15608700
references.citation: J Immunol. 2002 Oct 15;169(8):4098-102
references.pmid: 12370336
references.citation: Immunol Today. 1997 Feb;18(2):89-95
references.pmid: 9057360
references.citation: Hybridoma. 1991 Jun;10(3):347-56
references.pmid: 1916847
references.citation: Nat Rev Cancer. 2001 Nov;1(2):118-29
references.pmid: 11905803
references.citation: J Immunother. 1999 Nov;22(6):514-24
references.pmid: 10570750
references.citation: Nat Biotechnol. 2003 Dec;21(12):1486-92
references.pmid: 14634668
references.citation: Clin Cancer Res. 2005 Oct 15;11(20):7516-22
references.pmid: 16243826
references.citation: J Invest Dermatol. 2002 Apr;118(4):600-5
references.pmid: 11918705
references.citation: Nature. 2001 Sep 13;413(6852):165-71
references.pmid: 11557981
references.citation: Hum Immunol. 2006 Mar;67(3):183-7
references.pmid: 16698440
references.citation: Blood. 2000 Mar 15;95(6):2098-103
references.pmid: 10706880
references.citation: Nat Rev Immunol. 2006 Jul;6(7):520-31
references.pmid: 16799471
references.citation: Immunity. 2001 Aug;15(2):201-11
references.pmid: 11520456
references.citation: Immunity. 2001 Feb;14(2):123-33
references.pmid: 11239445
references.citation: Br J Cancer. 2000 Mar;82(5):1058-62
references.pmid: 10737389
references.citation: Nature. 1983 Oct 6-12;305(5934):537-40
references.pmid: 6137772
references.citation: Biochem Soc Trans. 2002 Aug;30(4):507-11
references.pmid: 12196124
references.citation: J Biol Chem. 2007 Apr 27;282(17):12650-60
references.pmid: 17347147
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2731-6
references.pmid: 10694580
references.citation: Nat Immunol. 2000 Aug;1(2):119-26
references.pmid: 11248803
references.citation: Blood. 1999 Oct 15;94(8):2562-8
references.pmid: 10515858
references.citation: Acta Pharmacol Sin. 2005 Jan;26(1):1-9
references.pmid: 15659107
references.citation: Int J Cancer. 1992 Aug 19;52(1):110-9
references.pmid: 1500216
references.citation: Hum Gene Ther. 2006 Feb;17(2):135-46
references.pmid: 16454647
references.citation: Cancer Res. 1996 Oct 15;56(20):4758-65
references.pmid: 8840995
references.citation: Biochem Biophys Res Commun. 2003 May 23;305(1):129-35
references.pmid: 12732206
references.citation: Int J Cancer. 1999 Apr 12;81(2):285-91
references.pmid: 10188732
references.citation: J Exp Med. 1984 Dec 1;160(6):1686-701
references.pmid: 6239899
references.citation: Blood. 2005 Jan 1;105(1):251-8
references.pmid: 15328155
references.citation: Science. 1999 Jul 30;285(5428):727-9
references.pmid: 10426993
references.citation: Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6259-63
references.pmid: 8022771
references.citation: Cancer Res. 2002 Nov 1;62(21):6178-86
references.pmid: 12414645
references.citation: Nat Rev Cancer. 2002 Nov;2(11):850-61
references.pmid: 12415255
references.citation: Nat Immunol. 2005 Sep;6(9):928-37
references.pmid: 16116470
references.citation: Nat Biotechnol. 1998 Jul;16(7):677-81
references.pmid: 9661204
references.citation: Blood. 2006 Mar 1;107(5):1955-62
references.pmid: 16210338
references.citation: Immunity. 2000 Jun;12(6):721-7
references.pmid: 10894171
references.citation: Methods Enzymol. 2000;322:325-45
references.pmid: 10914028
references.citation: J Immunol Methods. 2005 Jan;296(1-2):95-101
references.pmid: 15680154
references.citation: Cancer Immun. 2001 Mar 30;1:2
references.pmid: 12747763
references.citation: J Immunol. 2002 Oct 15;169(8):4079-83
references.pmid: 12370332
references.citation: Protein Eng. 1996 Jul;9(7):617-21
references.pmid: 8844834
references.citation: Mol Immunol. 1991 Sep;28(9):1027-37
references.pmid: 1922108
references.citation: J Exp Med. 1985 Jan 1;161(1):40-52
references.pmid: 2981954
references.citation: Cancer Res. 1998 Apr 1;58(7):1469-77
references.pmid: 9537250
references.citation: Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11521-6
references.pmid: 11562472
references.citation: Blood. 2003 Aug 15;102(4):1389-96
references.pmid: 12714493
references.citation: Annu Rev Immunol. 2001;19:197-223
references.pmid: 11244035
references.citation: Curr Top Microbiol Immunol. 1998;230:193-220
references.pmid: 9586357
references.citation: J Immunol. 1998 Oct 1;161(7):3501-9
references.pmid: 9759870
references.citation: J Clin Invest. 2008 Mar;118(3):994-1005
references.pmid: 18259610
references.citation: Nat Immunol. 2001 Mar;2(3):255-60
references.pmid: 11224526
references.citation: Br J Cancer. 2004 Oct 18;91(8):1495-9
references.pmid: 15381927